Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder
Frontiers in Psychiatry · 18.06.2026 · 17
DOI: 10.3389/fpsyt.2026.1812398 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 18.06.2026. Verfasst von Gia Linh Mac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju, Republic of Korea. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Attention-deficit/hyperactivity disorder (ADHD), a common neurodevelopmental condition, often requires treatment with stimulants such as methylphenidate and nonstimulants such as atomoxetine. Despite their effectiveness, medication-related side effects, adherence and symptom control issues have increased the interest in alternative therapies, especially herbal medicine. However, existing preclinical studies vary in quality and relevance. This systematic review evaluates animal studies investigating herbal medicines for ADHD; identifies limitations in experimental models, behavioral assessments, safety evaluation, and methodological rigor; and proposes a framework to guide future research.
Methods
Following PRISMA 2020 guidelines, PubMed and Web of Science were systematically searched for eligible studies published between 1995 and March 2025 that used animal models to interventions for the treatment of ADHD-like symptoms.
Results
Analysis of 25 studies revealed a strong reliance on a limited range of animal models, particularly the spontaneously hypertensive rat (48%), with 88% of studies using male animals exclusively. Behavioral assessments predominantly focused on hyperactivity (72%), whereas evaluations of inattention and impulsivity were comparatively limited. Herbal interventions were associated with improvements in ADHD-like behaviors and modulation of catecholaminergic neurotransmission, including increased dopamine and norepinephrine levels in the prefrontal cortex. Additional mechanisms included activation of neurotrophic signaling pathways (brain-derived neurotrophic factor/TrkB) and suppression of proinflammatory mediators such as TNF-α and IL-1β. However, 80% of the studies did not report safety outcomes, and no study clearly described randomization or blinding procedures, limiting the translational relevance of the findings. Despite these limitations, several formulations, including the Long Mu Qing Xin mixture, An Shen Ding Zhi Ling demonstrated promising multitarget effects.
Conclusion
Although herbal medicines demonstrate promising multipathway effects for ADHD, progress remains constrained by the limited diversity of animal models and narrow scope of behavioral assessments. Future research should prioritize the use of diverse models, more comprehensive assessments, and the implementation of rigorous methodological standards.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju, Republic of Korea.
- Department of Herbal Medicine, Dongguk University College of Korean Medicine, Gyeongju, Republic of Korea.
Zitieren
APA
Mac, G. L., Tran, K. N., Tran, T. D., Shao, H., Wang, Y., Park, K. H., Jung, H. W., & Yang, I. J. (2026). Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1812398
Vancouver
Mac GL, Tran KN, Tran TD, Shao H, Wang Y, Park KH, et al. Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1812398
BibTeX
@article{Mac2026,
author = {Mac, Gia Linh and Tran, Khoa Nguyen and Tran, Tien Dat and Shao, Haifeng and Wang, Yang and Park, Kyung-Hee and Jung, Hyo-Won and Yang, In-Jun},
title = {Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1812398}
}
EUVIMED